You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Article metrics

Article menu

Download PDFPDF

XML
Clinical trials monitor
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

 

Online download statistics by month:

Online download statistics by month: June 2020 to August 2024

AbstractFullPdf
Jun 2020335335167
Jul 202015615648
Aug 2020596038
Sep 2020616131
Oct 2020808063
Nov 2020353516
Dec 2020505017
Jan 2021797921
Feb 2021616111
Mar 202112312330
Apr 2021848438
May 2021676728
Jun 2021848441
Jul 2021747435
Aug 2021707037
Sep 2021979733
Oct 2021595940
Nov 2021737447
Dec 2021717226
Jan 2022767720
Feb 2022434316
Mar 202211912936
Apr 202221121535
May 202219119540
Jun 202216016231
Jul 202217817923
Aug 202215115236
Sep 202216316553
Oct 202215615940
Nov 202213713737
Dec 202213813819
Jan 202312712828
Feb 202313513638
Mar 202315815927
Apr 202310110124
May 202313313318
Jun 202314114222
Jul 202314114326
Aug 202315615615
Sep 202312912914
Oct 202311211214
Nov 202316916925
Dec 202319920023
Jan 202412812826
Feb 202415715739
Mar 2024119120112
Apr 2024696939
May 2024757652
Jun 2024696926
Jul 202411711823
Aug 2024424219
Total591859591763